Incyte (INCY) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
February 14, 2019 7:00 AM ESTTotal product-related revenues of $468 million (+25%) in 4Q 2018 and $1.7 billion (+25%) for the full year 2018 Jakafi® (ruxolitinib) revenues of $380 million (+26%) in 4Q 2018 and $1.4 billion (+22%) for the full year 2018 Multiple late-stage product candidates provide additional opportunities to further accelerate revenue growth
Conference Call and Webcast Scheduled Today at 8:00 a.m. EST
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a... More
